Botulinum Toxin in Movement Disorders: An Update
Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disor...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/13/1/42 |
| _version_ | 1797414444787040256 |
|---|---|
| author | Charenya Anandan Joseph Jankovic |
| author_facet | Charenya Anandan Joseph Jankovic |
| author_sort | Charenya Anandan |
| collection | DOAJ |
| description | Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson’s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies. |
| first_indexed | 2024-03-09T05:33:07Z |
| format | Article |
| id | doaj.art-4cfba40a46bb4b14964245fbdb44be00 |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-03-09T05:33:07Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-4cfba40a46bb4b14964245fbdb44be002023-12-03T12:30:43ZengMDPI AGToxins2072-66512021-01-011314210.3390/toxins13010042Botulinum Toxin in Movement Disorders: An UpdateCharenya Anandan0Joseph Jankovic1Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USAParkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USASince its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson’s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies.https://www.mdpi.com/2072-6651/13/1/42botulinum toxinmovement disorderstremorsdystoniaticsbruxism |
| spellingShingle | Charenya Anandan Joseph Jankovic Botulinum Toxin in Movement Disorders: An Update Toxins botulinum toxin movement disorders tremors dystonia tics bruxism |
| title | Botulinum Toxin in Movement Disorders: An Update |
| title_full | Botulinum Toxin in Movement Disorders: An Update |
| title_fullStr | Botulinum Toxin in Movement Disorders: An Update |
| title_full_unstemmed | Botulinum Toxin in Movement Disorders: An Update |
| title_short | Botulinum Toxin in Movement Disorders: An Update |
| title_sort | botulinum toxin in movement disorders an update |
| topic | botulinum toxin movement disorders tremors dystonia tics bruxism |
| url | https://www.mdpi.com/2072-6651/13/1/42 |
| work_keys_str_mv | AT charenyaanandan botulinumtoxininmovementdisordersanupdate AT josephjankovic botulinumtoxininmovementdisordersanupdate |